IL17A and neoplasm: Prior reports have suggested that IL‐17 inhibition helps augment tumor immunity by enhancing cytotoxic CD8+ T cells and Th1 cells in the TME.[34] Therefore, after combining GLS inhibition with EVax vaccination, we noticed a CD4+ T cell landscape with anti‐tumor Th1 cells as the major cell type.